UCB Unifies Global Pharmacovigilance Operations with Veeva Safety Suite

Veeva Systems (NYSE: VEEV) announced that biopharma company UCB is unifying its global pharmacovigilance operations on Veeva Safety Suite.

Rhea-AI Summary

Veeva Systems (NYSE: VEEV) announced that biopharma company UCB is unifying its global pharmacovigilance operations on Veeva Safety Suite. UCB will standardize safety case intake, processing, submissions, content management, signal detection, and regulatory data sharing on a single platform to improve efficiency, automation, and global oversight.

Argus Jun 9 session

+0.26% close to close Open Argus

Details

News Market Reaction – VEEV

On Jun 9, the day this news came out, VEEV closed 0.26% above the previous close.

Data tracked by StockTitan Argus for the Jun 9 session.

Historical Context

5 past events · Latest: Jun 03

5 events

1. Jun 03

   Earnings results

   24h Move

   -0.1%

   Reported Q1 revenue growth of 16% and raised fiscal 2027 guidance.

2. May 28

   Customer win

   24h Move

   +3.7%

   Kindeva adopted Veeva Quality Cloud to unify global manufacturing quality.

3. May 27

   Product launch

   24h Move

   -0.0%

   Launched Veeva Falcon agentic platform for key drug development workflows.

4. May 27

   CRM deployment

   24h Move

   -0.0%

   Teva committed to deploy Veeva Vault CRM globally as a commercial foundation.

5. May 27

   CRM deployment

   24h Move

   -0.0%

   Merck KGaA selected Veeva Vault CRM worldwide to support healthcare operations.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pharmacovigilance, adverse events, signal detection, regulatory

4 terms

pharmacovigilance medical

""UCB is building a foundation powered by Veeva Safety Suite to simplify and standardize their global pharmacovigilance function""

Pharmacovigilance is the process of monitoring and assessing the safety of medicines after they are on the market, ensuring that any side effects or risks are identified and managed. For investors, it matters because it helps ensure that pharmaceutical companies maintain safe products, which can influence a company’s reputation, regulatory approval, and financial stability over time.

adverse events medical

"streamline the intake, processing, and submission of adverse events and Veeva SafetyDocs"

Adverse events are any harmful or unwanted medical occurrences experienced by people using a drug, device, or undergoing a treatment, whether or not the problem is caused by the product. Think of them as complaints or breakdowns noticed during a trial or after a product is on the market; regulators record and investigate them. Investors care because clusters or serious adverse events can delay approvals, trigger costly studies or recalls, change labeling, and quickly alter a company’s revenue and risk profile.

signal detection medical

"Veeva Safety Signal will automate signal detection for better visibility and alignment"

Signal detection is the ongoing process of spotting meaningful patterns, warnings or trends within large volumes of noisy data — whether that means early safety concerns about a product, unusual market movements, or emerging business risks. Like hearing a single voice in a crowded room, it helps analysts separate real issues from random noise so investors can act sooner on potential threats or opportunities, manage risk, and adjust valuations or positions accordingly.

regulatory regulatory

"share product information automatically across regulatory and safety operations for clean"

Relating to rules, government agencies, and official approvals that control how companies operate, what products they can sell, and how transactions are reported. For investors, regulatory matters matter because they can change a business’s costs, legal risks, or ability to sell products — like a traffic light that can slow, stop, or clear the flow of a company’s growth and profits. Regulatory actions or changes can therefore affect stock value and investment risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

End-to-end safety foundation to speed case processing and enable automation

PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that UCB is unifying its global safety operations with Veeva Safety Suite to maximize operational efficiency and scale. UCB is standardizing safety on a single platform to accelerate case processing, strengthen oversight, and streamline submissions to health authorities.

"Moving our teams onto Veeva Safety Suite is a core step in UCB's safety transformation, helping streamline global and local workflows with a single source of truth for safety data," said Jonas Maselis, head of digital technology, patient safety, UCB. "As we use automation to drive low-touch case processing, our strategic partnership with Veeva positions us well for what's next."

UCB will use Veeva Safety Suite's unified platform for end-to-end safety management, with Veeva Safety to streamline the intake, processing, and submission of adverse events and Veeva SafetyDocs to manage all safety-related content and processes. Veeva Safety Workbench will enable advanced data analysis for fast, scalable reporting, and Veeva Safety Signal will automate signal detection for better visibility and alignment across the organization. In addition, the Veeva Safety-RIM Connection will share product information automatically across regulatory and safety operations for clean and trusted data.

"UCB is building a foundation powered by Veeva Safety Suite to simplify and standardize their global pharmacovigilance function," said John Lawrie, vice president, Veeva Safety. "With a unified and connected approach, UCB is enhancing global compliance and driving advanced automation to deliver safe and effective medicines to patients."

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, AI, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Elizabeth McGrane
Veeva Systems
elizabeth.mcgrane@veeva.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ucb-unifies-global-pharmacovigilance-operations-with-veeva-safety-suite-302794672.html

SOURCE Veeva Systems

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Veeva Systems (VEEV) announce about UCB on June 9, 2026?

Veeva Systems announced that UCB will unify its global pharmacovigilance operations on Veeva Safety Suite. According to Veeva, UCB will use the unified platform to streamline case processing, strengthen oversight, and standardize safety processes worldwide.

How will UCB use Veeva Safety Suite to manage global pharmacovigilance operations?

UCB plans to use Veeva Safety Suite as an end-to-end safety platform covering intake, processing, and submissions. According to Veeva, UCB will also centralize safety content, signal detection, and regulatory product data sharing to support consistent, trusted safety information.

Which Veeva Safety Suite products will UCB deploy for its safety operations?

UCB will deploy Veeva Safety, Veeva SafetyDocs, Veeva Safety Workbench, Veeva Safety Signal, and the Veeva Safety-RIM Connection. According to Veeva, these products support case management, content, analytics, signal detection, and regulatory data integration.

What benefits does UCB expect from adopting Veeva Safety Suite for pharmacovigilance?

UCB expects improved operational efficiency, faster case processing, and stronger global oversight by using one safety platform. According to Veeva, the suite also supports advanced automation, low-touch case processing, standardized workflows, and enhanced compliance with health authority requirements.

How does Veeva Safety Suite support automation in UCB’s safety case processing?

Veeva Safety Suite is intended to enable automation and low-touch case processing across UCB’s safety workflows. According to UCB and Veeva, unified data, integrated tools, and automated signal detection help reduce manual tasks and support faster, scalable safety reporting.

What role does the Veeva Safety-RIM Connection play in UCB’s safety operations?

The Veeva Safety-RIM Connection will automatically share product information across regulatory and safety operations. According to Veeva, this integration supports clean, trusted data, aligning pharmacovigilance activities with regulatory records for improved data consistency and operational oversight.